FLGT
Fulgent Genetics, Inc.
FLGT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
FLGT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
FLGT's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
FLGT PE Valuation
FLGT has no meaningful PE right now: it lost money over the past year.
FLGT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect FLGT's losses to grow, with revenue growing.
FLGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$1.71 |
| Q2 2026 | -$2.83 | -$1.17 |
| Q1 2026 | -$2.40 | -$1.07 |
| Q4 2025 | -$1.97 | -$0.56 |
| Q3 2025 | -$1.39 | +$4.12 |
| Q2 2025 | -$1.66 | +$3.81 |
| Q1 2025 | -$1.33 | +$4.23 |
| Q4 2024 | -$1.41 | +$4.22 |
FLGT lost $3.10 per share over the past year, and its loss has widened in each of the last four quarters.
FLGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $90.4M | +7.5% |
| Q2 2026 | $85.4M | +4.4% |
| Q1 2026 | $71.1M | -3.2% |
| Q4 2025 | $83.3M | +9.3% |
| Q3 2025 | $84.1M | +17% |
| Q2 2025 | $81.8M | +15% |
| Q1 2025 | $73.5M | +14% |
| Q4 2024 | $76.2M | +8.1% |
FLGT's revenue is recovering but still below its 2021 peak: $90M last quarter, up 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | -6.7 points |
| Q2 2026 | -42% | -18 points |
| Q1 2026 | -49% | -22 points |
| Q4 2025 | -43% | -22 points |
| Q3 2025 | -18% | +5.5 points |
| Q2 2025 | -24% | +2.5 points |
| Q1 2025 | -27% | +6.8 points |
| Q4 2024 | -21% | +193 points |
FLGT's operating margin was −25% last quarter, down 6.7 points from the same quarter a year ago.
FLGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $107.4M | +2025% |
| Q2 2026 | -$27.6M | +$9.4M |
| Q1 2026 | $1.9M | +$11M |
| Q4 2025 | -$83.1M | -491% |
| Q3 2025 | $5.1M | +$40.1M |
| Q2 2025 | -$37M | -$28.3M |
| Q1 2025 | -$9.1M | -385% |
| Q4 2024 | $21.2M | +80% |
FLGT's free cash flow was −$1M over the past year, against −$20M the year before.
FLGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.4x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.6x | Net Cash |
| Q4 2021 | -0.2x | Net Cash |
| Q3 2021 | -0.3x | Net Cash |
| Q2 2021 | -0.1x | Net Cash |
| Q1 2021 | -0.3x | Net Cash |
FLGT has more cash than debt.
FLGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 79.5 | Neutral |
FLGT's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
FLGT PE vs Healthcare Sector
| Metric | FLGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
FLGT has no meaningful PE right now: it lost money over the past year.
FLGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.8 | 14% above |
| 20 week MA | $20.6 | 21% above |
| 50 week MA | $20.5 | 22% above |
| 100 week MA | $20.4 | 22% above |
| 200 week MA | $23.7 | 4.9% above |
FLGT has climbed back above all five of its weekly moving averages, and it's now 4.9% above its 200-week average.
FLGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.2 | $45.8 | +246% |
| 2021 | $45.8 | $100.2 | +119% |
| 2022 | $100.2 | $30.3 | -70% |
| 2023 | $30.3 | $28.9 | -4.7% |
| 2024 | $28.9 | $18.4 | -36% |
| 2025 | $18.4 | $26.7 | +45% |
| 2026 YTD | $26.7 | $24.9 | -7% |
FLGT's yearly returns have swung widely, from +246% in 2020 to −70% in 2022. It's down 7% so far in 2026.